Claiming that the drug is more of destructive than the good it is intended to do, World Health Organisation(WHO) has temporarily halted its clinical trials that use hydroxychloroquine(HCQ) to treat COVID-19 patients. In the support of its claim, the esteem organisation put forth the recent study which reported that the anti-malarial drug could increase the mortality in coronavirus patients.
WHO Director-General Tedros cited the British journal The Lancet which published findings showing that hydroxychloroquine doesn’t help COVID-19 patients and might even increase deaths. While WHO has 3,500 patients from 17 countries enrolled in what it calls the Solidarity Trial, Dr Soumya Swaminathan, the WHO’s chief scientist, said the organization’s investigators and regulators in individual countries reported that patients getting HCQ were dying at higher rates than other coronavirus patients.
Countries that have allowed the use of HCQ for Covid-19, with restrictions, include the US (for emergency use in hospital), France (on prescription), Brazil, Russia and South Korea. On the other hand, the US Food and Drug Administration claimed that FDA is aware of reports of serious heart rhythm problems in patients with COVID-19 treated with hydroxychloroquine or chloroquine. It then turned debatable if the US is risking the lives of patients. This move came close on the heels of the US President Donald Trump continued to push for HCQ, including that he had “just finished” taking the drug after a two-week course.